Prevalence and Impact of Cirrhotic Cardiomyopathy on Adverse Outcomes Following Liver Transplantation: A Systematic Review and a Meta-Analysis [0.03%]
肝移植后心肌病对不良影响的流行率及其作用的系统评价和meta分析
Ramish Sumbal,Raja T Yaseen Khan,Muhammad Q Panezai et al.
Ramish Sumbal et al.
Background: Approximately 30-50% of liver transplant patients have underlying cirrhotic cardiomyopathy (CCM), which may contribute to post-transplant complications such as mortality and heart failure (HF). However, the re...
Sagnik Biswas,Shalimar
Sagnik Biswas
Impact of Acculturation Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Among Mexican Americans [0.03%]
文化适应对墨西哥裔美国人代谢功能障碍相关肝脂肪变性疾病的影响
Rithvik Vutukuri,Sharan Poonja,Molly Delk et al.
Rithvik Vutukuri et al.
Background/aims: Latin America holds the highest global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), affecting up to 44.4% of the population. With the growing Hispanic population in the ...
The Changing Paradigm of Etiology in Acute Liver Failure in India: Hepatitis E to A [0.03%]
印度急性肝衰竭病因范式的转变：由戊型肝炎变为甲型肝炎
Vipul Gautam,Subhash Gupta,Sanjiv Saigal
Vipul Gautam
Clinical Determinants of Delayed Diagnosis in Wilson's Disease: Misdiagnosis Patterns, Phenotypes, and Impact on Survival [0.03%]
威尔森病延迟诊断的临床决定因素：误诊模式、表型及对生存率的影响
Yavuz Özden,Osman Sağlam
Yavuz Özden
Background/aims: Diagnostic delay in Wilson's disease (WD) remains common because of marked phenotypic heterogeneity. Although neuropsychiatric presentations are known to delay recognition, quantitative evidence linking d...
Endo-Hepatology and Artificial Intelligence: New Avenues for Diagnosis and Intervention [0.03%]
内分泌肝病与人工智能：诊断和介入的新途径
Goutham Reddy Katukuri,Rakesh Kalapala
Goutham Reddy Katukuri
Artificial intelligence (AI) is gaining momentum in the field of endo-hepatology, offering potential improvements in diagnosis, risk stratification, and procedural outcome prediction. This review outlines AI applications across endoscopic d...
Delineating Metabolic Dysfunction-Associated Steatotic Liver Disease and Comorbid Risk With Clinical, Blood and Metabolomic Parameters-A UK Biobank Analysis [0.03%]
代谢功能异常相关脂肪肝病及其共病风险的临床、血液和代谢组学参数特征——来自英国生物样本库的分析研究
Brian Ho,Yun Xu,Christopher E Goldring et al.
Brian Ho et al.
Background/objectives: Ascertaining risk of and prognostication tools for metabolic dysfunction-associated steatotic liver disease (MASLD) remain suboptimal. Using the UK Biobank, we investigated the role of multivariate ...
Alpha-1 Antitrypsin Deficiency Alleles in Non-Cirrhotic Hepatocellular Carcinoma: Insights from a Multicenter French Cohort [0.03%]
法国多中心队列中非肝硬化 hepatocellular carcinoma患者中的α-1抗胰蛋白酶缺陷型allele分布特点及启示
Aurélie Beaufrère,Celine Leon,Marie Decreaker et al.
Aurélie Beaufrère et al.
Background & aims: Patients with alpha-1 antitrypsin deficiency (AATD) have a 20- to 50-fold higher risk of developing primary liver cancer (PLC), such as hepatocellular carcinoma (HCC), in both cirrhotic and noncirrhotic...
Difficult to Treat Autoimmune Hepatitis: A Pediatric Hepatology Perspective [0.03%]
难治性自身免疫性肝炎：儿科肝脏病学观点
Samannay Das,Tamoghna Biswas
Samannay Das
Hepatocellular Carcinoma in Non-cirrhotic Portal Fibrosis/Idiopathic Portal Hypertension: An Under-recognized Complication-A Case Report and Literature Review [0.03%]
非肝硬化门脉纤维化/特发性门静脉高压症肝细胞癌病例报告及文献复习
Ankita Singh,Sidharth Harindranath,Prabhsaran Kaur et al.
Ankita Singh et al.
Vascular liver diseases are recognized risk factors for the development of hepatocellular carcinoma (HCC) in non-cirrhotic livers. While the association is well established in conditions like Budd-Chiari syndrome, which have defined surveil...